Mardi Dier - Net Worth and Insider Trading
Mardi Dier Net Worth
The estimated net worth of Mardi Dier is at least $4 Million dollars as of 2024-04-27. Mardi Dier is the CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc and owns about 66,695 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $3 Million. Mardi Dier is the EVP, CFO & CBO of Portola Pharmaceuticals Inc and owns about 66,733 shares of Portola Pharmaceuticals Inc (PTLA) stock worth over $1 Million. Mardi Dier is also the Director of Prelude Therapeutics Inc and owns about 10,000 shares of Prelude Therapeutics Inc (PRLD) stock worth over $40,700. Besides these, Mardi Dier also holds Acelyrin Inc (SLRN) . Details can be seen in Mardi Dier's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mardi Dier has not made any transactions after 2023-05-09 and currently still holds the listed stock(s).
Transaction Summary of Mardi Dier
Mardi Dier Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mardi Dier owns 6 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , Prelude Therapeutics Inc (PRLD) , and Portola Pharmaceuticals Inc (PTLA) among others .
Click here to see the complete history of Mardi Dier’s form 4 insider trades.
Insider Ownership Summary of Mardi Dier
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
RARE | Ultragenyx Pharmaceutical Inc | 2022-10-14 | CFO & Executive Vice President |
PRLD | Prelude Therapeutics Inc | 2020-09-29 | director |
PTLA | Portola Pharmaceuticals Inc | 2020-07-02 | EVP and CFO |
ADMS | Adamas Pharmaceuticals Inc | 2020-06-03 | director |
ORIC | ORIC Pharmaceuticals Inc | 2020-04-23 | director |
SLRN | Acelyrin Inc | 2023-05-09 | CFO and CBO |
Mardi Dier Latest Holdings Summary
Mardi Dier currently owns a total of 4 stocks. Among these stocks, Mardi Dier owns 66,695 shares of Ultragenyx Pharmaceutical Inc (RARE) as of October 14, 2022, with a value of $3 Million and a weighting of 69.83%. Mardi Dier owns 66,733 shares of Portola Pharmaceuticals Inc (PTLA) as of April 4, 2019, with a value of $1 Million and a weighting of 28.47%. Mardi Dier also owns 10,000 shares of Prelude Therapeutics Inc (PRLD) as of September 29, 2020, with a value of $40,700 and a weighting of 0.96%. The other 1 stocks Acelyrin Inc (SLRN) have a combined weighting of 0.73% among all his current holdings.
Latest Holdings of Mardi Dier
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
RARE | Ultragenyx Pharmaceutical Inc | 2022-10-14 | 66,695 | 44.24 | 2,950,587 |
PTLA | Portola Pharmaceuticals Inc | 2019-04-04 | 66,733 | 18.03 | 1,203,196 |
PRLD | Prelude Therapeutics Inc | 2020-09-29 | 10,000 | 4.07 | 40,700 |
SLRN | Acelyrin Inc | 2023-05-09 | 7,306 | 4.24 | 30,977 |
Holding Weightings of Mardi Dier
Mardi Dier Form 4 Trading Tracker
According to the SEC Form 4 filings, Mardi Dier has made a total of 4 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 1,629 shares on October 14, 2022, which brought Mardi Dier around $65,421.
According to the SEC Form 4 filings, Mardi Dier has made a total of 0 transactions in Portola Pharmaceuticals Inc (PTLA) over the past 5 years. The most-recent trade in Portola Pharmaceuticals Inc is the sale of 40,486 shares on April 4, 2019, which brought Mardi Dier around $2 Million.
According to the SEC Form 4 filings, Mardi Dier has made a total of 1 transactions in Prelude Therapeutics Inc (PRLD) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prelude Therapeutics Inc is the acquisition of 10,000 shares on September 29, 2020, which cost Mardi Dier around $190,000.
More details on Mardi Dier's insider transactions can be found in the Insider Trading History of Mardi Dier table.Insider Trading History of Mardi Dier
- 1
Mardi Dier Trading Performance
GuruFocus tracks the stock performance after each of Mardi Dier's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mardi Dier is 97.52%. GuruFocus also compares Mardi Dier's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mardi Dier within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mardi Dier's insider trading performs compared to the benchmark.
Performance of Mardi Dier
Average Return
7.14%
Outperforming Transactions
100%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | -1.83 | 97.52 | -15.21 | 7.14 | -52.45 | -52.5 |
Relative Return to S&P 500(%) | -3.63 | 87.42 | -27.51 | -23.56 | -56.92 | -61.23 |
Mardi Dier Ownership Network
Ownership Network List of Mardi Dier
Ownership Network Relation of Mardi Dier
Mardi Dier Owned Company Details
What does Ultragenyx Pharmaceutical Inc do?
Who are the key executives at Ultragenyx Pharmaceutical Inc?
Mardi Dier is the CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include EVP and Chief Medical Officer Eric Crombez , CBO & Senior Vice President Thomas Richard Kassberg , and EVP and General Counsel Karah Herdman Parschauer .
Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary
Over the past 18 months, Mardi Dier made no insider transaction in Ultragenyx Pharmaceutical Inc (RARE). Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 5,605 shares made by Theodore Alan Huizenga , a net sale of 127,435 shares made by Emil D Kakkis , and a net sale of 54,366 shares made by Thomas Richard Kassberg .
In summary, during the past 3 months, insiders sold 69,133 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 69,133 shares. During the past 18 months, 243,293 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 243,293 shares.
Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ultragenyx Pharmaceutical Inc Insider Transactions
Mardi Dier Mailing Address
Above is the net worth, insider trading, and ownership report for Mardi Dier. You might contact Mardi Dier via mailing address: C/o Acelyrin, Inc., 4149 Liberty Canyon Rd., Agoura Hills Ca 91301.